glp 1 gut microbiota A sympathetic brake on GLP-1 release: Neuron Implement enhanced artificial “enteroendocrine L

A critical consideration is that diabetes itself substantially increases gastroparesis riskaffecting up to 5% of patients with type 1 diabetes and 1% with type 2 diabetes

Litigation over Ozempic and Wegovy has expanded beyond gastrointestinal injuries, with over 30 plaintiffs now alleging that use of the drugs led to vision loss caused by nonarteritic anterior ischemic optic neuropathy (NAION), a condition that can cause permanent blindness

[DOI] [PubMed] [Google Scholar] 98.European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASDEASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) J Hepatol

Additionally, GLP-1 receptor agonists have demonstrated dual benefits in reducing headache symptoms and promoting weight loss in patients with idiopathic intracranial hypertension, offering therapeutic advantages for conditions involving both metabolic dysregulation and chronic pain 63